Navigating the Labyrinth: An In-Depth Analysis of Insurance Coverage for Zepbound

Section 1: Zepbound – A Clinical and Market Overview

The emergence of Zepbound into the therapeutic landscape represents a significant advancement in the medical management of obesity and its related comorbidities.

To fully comprehend the complexities of its insurance coverage, one must first possess a foundational understanding of the drug’s clinical profile, its manufacturer, its approved uses, and the robust data supporting its efficacy and safety.

These elements collectively establish the drug’s value proposition, which is the central focus of negotiations and coverage decisions by healthcare payers.

1.1. Introduction to Tirzepatide: The Dual-Agonist Mechanism

Zepbound’s active ingredient is tirzepatide, a novel molecule that distinguishes itself as the first and only approved treatment for chronic weight management that activates two distinct hormone receptors: the glucose-dependent insulinotropic polypeptide (GIP) and the glucagon-like peptide-1 (GLP-1).¹

These naturally occurring incretin hormones are secreted by the intestine and play a crucial role in metabolic regulation.

By acting as a dual GIP and GLP-1 receptor agonist, Zepbound is engineered to tackle an underlying physiological driver of excess weight.³

The activation of these receptors in the brain and body works synergistically to reduce appetite and decrease food intake, effectively helping to recalibrate the body’s energy balance.⁵

This dual-agonist mechanism of action is a key differentiator from previous generations of weight management medications, including single-agonist GLP-1 drugs like semaglutide (the active ingredient in Wegovy and Ozempic), and forms the basis of its superior clinical trial performance.⁶

This distinction is not merely academic; it becomes a critical point of argument in appeals against insurance policies that require patients to try and fail a single-agonist GLP-1 before granting access to Zepbound.

1.2. Manufacturer Profile: Eli Lilly and Company

Zepbound is developed, manufactured, and marketed by Eli Lilly and Company, a US-based global pharmaceutical corporation with a long-standing and extensive portfolio in metabolic diseases, particularly diabetes and, more recently, obesity.²

Lilly’s role extends far beyond manufacturing; the company has established a comprehensive ecosystem of patient support services designed to navigate the very access challenges this report details.

This ecosystem includes Lilly Support Services, accessible via a central phone number (1-800-LillyRx), and LillyDirect, a digital healthcare platform that offers disease management resources and, critically, a direct-to-consumer pharmacy pathway for select Lilly medicines, including Zepbound.³

This direct channel allows patients to purchase the medication, often at a lower cash price than the retail list price, bypassing traditional pharmacy benefit managers (PBMs) and insurance hurdles.

Additionally, the Lilly Cares Foundation, a separate nonprofit entity, offers a patient assistance program (PAP) for those with significant financial need.⁹

It is imperative to distinguish between authentic, FDA-approved Zepbound manufactured by Eli Lilly and unapproved “compounded” versions of tirzepatide offered by some pharmacies and medical practices.⁷

The U.S. Food and Drug Administration (FDA) has issued warnings regarding the safety and efficacy of these compounded products, which are not subject to the same rigorous quality and safety reviews as FDA-approved medications and may contain incorrect or even harmful ingredients.⁷

Insurance plans will not cover these non-approved compounded drugs.¹³

1.3. FDA-Approved Indications: The Strategic Importance of Diagnosis

The specific FDA-approved indications for tirzepatide, under its two brand names Zepbound and Mounjaro, are of paramount strategic importance when seeking insurance coverage.

Payers often have different rules and levels of willingness to cover drugs based on their approved use, creating an “indication hierarchy” that can be navigated to improve the chances of approval.

• Chronic Weight Management: Zepbound received its initial FDA approval on November 8, 2023. It is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with obesity, defined as a body mass index (BMI) of 30 kg/m2 or greater, or those who are overweight (BMI of 27 kg/m2 or greater) and have at least one weight-related comorbid condition.¹ These conditions include hypertension (high blood pressure), dyslipidemia (high cholesterol), type 2 diabetes mellitus, or cardiovascular disease.¹ While this is the primary indication, it is also the one most likely to encounter payer resistance and “weight loss plan exclusions”.¹⁵
• Obstructive Sleep Apnea (OSA): Zepbound later gained an additional FDA approval for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.² This indication provides a powerful alternative pathway for securing coverage. Many insurance plans that exclude medications solely for weight loss may cover treatments for a distinct and serious medical condition like OSA. A prescription for Zepbound with a primary diagnosis of OSA can therefore bypass a plan’s general anti-obesity drug exclusion.
• The Mounjaro Connection: The active ingredient, tirzepatide, was first approved by the FDA in May 2022 under the brand name Mounjaro for improving glycemic control in adults with type 2 diabetes mellitus.² This is the most robustly covered indication. Because type 2 diabetes is almost universally considered a medical necessity for treatment by payers, Mounjaro typically faces fewer coverage hurdles than Zepbound. The fact that Zepbound and Mounjaro are the same drug sold for different indications is a source of immense confusion and frustration but also a key to understanding the logic of the insurance system. A patient with obesity and type 2 diabetes may be denied Zepbound but approved for Mounjaro.

Eli Lilly’s strategic approach—securing approval first for diabetes, then for general obesity, and finally for a specific, high-morbidity comorbidity like OSA—appears deliberately designed to dismantle payer barriers one by one.

This multi-pronged strategy creates several distinct clinical justifications for the drug’s use, systematically expanding the pool of patients for whom coverage can be successfully argued and normalizing tirzepatide as a standard of care for metabolic disease.

It is a critical limitation of use that Zepbound should not be taken concurrently with other tirzepatide-containing products (i.e., Mounjaro) or with any other GLP-1 receptor agonist medicines.¹

1.4. Clinical Efficacy: A Review of the SURMOUNT Trial Data

The powerful clinical efficacy of Zepbound, demonstrated in the landmark SURMOUNT clinical trial program, provides the scientific foundation for its use and serves as compelling evidence in medical necessity appeals.

• SURMOUNT-1 and SURMOUNT-2 Trials: These two randomized, double-blind, placebo-controlled studies established Zepbound’s effectiveness for chronic weight management.⁵

• In the SURMOUNT-1 trial, which involved adults with obesity or overweight but without type 2 diabetes, patients taking the highest dose of Zepbound (15 mg) for 72 weeks lost an average of 20.9% of their body weight, or 48 pounds.² Those on the lowest maintenance dose (5 mg) lost an average of 15.0%, or 34 pounds, compared to just 3.1% (7 pounds) for those on placebo.²
• In the SURMOUNT-2 trial, which studied adults with both obesity or overweight and type 2 diabetes, patients on the 15 mg dose experienced average weight reductions of 15.7% (34.4 pounds) over 72 weeks, compared to 3.3% (7.0 pounds) for placebo.²
• SURMOUNT-5 Trial (Head-to-Head vs. Wegovy): The results of the SURMOUNT-5 clinical trial are particularly significant for navigating insurance step therapy requirements. This trial directly compared tirzepatide (Zepbound) to semaglutide (Wegovy) and demonstrated that Zepbound led to significantly greater weight loss over a 72-week period.⁶ This evidence, published in a major medical journal, can be cited in appeals to argue that forcing a patient to “fail first” on the less effective Wegovy is not clinically appropriate.

1.5. Safety Profile, Warnings, and Contraindications

A thorough understanding of Zepbound’s safety profile is essential, as contraindications and potential side effects are integral to prescribing decisions and are often explicitly referenced in insurance coverage criteria.

• Boxed Warning: Zepbound carries the FDA’s most serious warning, a boxed warning, for the risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC).¹ Due to this risk, observed in rodent studies, Zepbound is contraindicated and must not be used in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).¹ This is a primary safety screen for all payers.
• Common Adverse Reactions: The most frequently reported side effects are gastrointestinal in nature and tend to be most prominent during the dose-escalation phase. These include nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia (indigestion), belching, and gastroesophageal reflux disease (heartburn).² Fatigue, injection site reactions, and hair loss have also been reported.²
• Serious Warnings and Precautions: Beyond the boxed warning, Zepbound’s label includes warnings for several other potentially serious conditions that insurers will scrutinize during a prior authorization review.⁵ These include:

• Inflammation of the pancreas (pancreatitis)
• Gallbladder problems (cholelithiasis, cholecystitis)
• Acute kidney injury
• Severe gastrointestinal disease (it has not been studied in patients with severe gastroparesis)
• Serious hypersensitivity (allergic) reactions
• Hypoglycemia (low blood sugar), particularly when used with other diabetes medications like insulin or sulfonylureas
• Diabetic retinopathy complications in patients with type 2 diabetes
• Suicidal behavior or ideation
• Drug and Other Interactions: The medication can affect the absorption of oral medicines. Notably, it may reduce the efficacy of oral hormonal contraceptives. Patients using birth control pills are advised to use a non-oral contraceptive method or add a barrier method for 4 weeks after starting Zepbound and for 4 weeks after each dose increase.⁶

Section 2: The Financial Realities of Zepbound: Cost and Assistance Programs

The high price of Zepbound is the single greatest barrier to access.

The list price set by the manufacturer is the starting point for a complex web of negotiated discounts, insurance copayments, and patient assistance programs.

Navigating this financial landscape is as crucial as navigating the clinical requirements for a prescription.

Eli Lilly has created a sophisticated, multi-tiered affordability structure designed to capture revenue from different patient populations while mitigating the access challenges created by the high list price and restrictive insurance coverage.

This structure effectively segments the market, providing distinct pathways for patients depending on their insurance status.

2.1. Deconstructing the Price: List Price vs. Out-of-Pocket Costs

The manufacturer’s list price for Zepbound is a benchmark figure that is rarely the final cost for most patients.

However, it serves as the anchor for all subsequent pricing and negotiations.

The list price for a 28-day supply of Zepbound single-dose pens is approximately $1,060 to $1,087, depending on the source and time of reporting.²¹

Without any form of insurance or discount, this would translate to a prohibitive annual cost of over $13,800.²¹

It is important to note that this list price is strategically set below that of its main competitor, Wegovy (semaglutide), which has a list price of around $1,350 per month.²¹

This price difference can be a factor in negotiations between the manufacturers and the PBMs that manage drug formularies for insurance companies.

The following table provides a consolidated matrix of potential costs, organizing the various options according to a patient’s specific insurance situation.

This tool is designed to help users quickly identify the financial pathways available to them.

Table 2.1: Zepbound Cost & Savings Program Matrix

Patient Insurance Status	Program/Option	Expected Out-of-Pocket Cost (per month)	Key Eligibility & Terms	Source(s)
Commercial Insurance	Zepbound Savings Card	As low as $25 for a 1- or 3-month supply	Plan must cover Zepbound. Max savings of $150/mo. Annual cap of ~$1,800-$1,950.	25
(with Zepbound coverage)
Commercial Insurance	Zepbound Savings Card	~$550 – $650 for a 1-month supply	Plan does not cover Zepbound. Savings of up to ~$563 off list price.	23
(without Zepbound coverage)
Uninsured / Self-Pay	LillyDirect Pharmacy	$349 (2.5 mg dose vial)	Cash-pay option. Requires prescription.	18
	(Single-Dose Vial)	$499 (5 mg – 15 mg dose vials)	Must self-draw injection.	25
	LillyDirect Pharmacy	$399 (2.5 mg dose pen)	Cash-pay option. New single-use pen pricing.	21
	(Single-Dose Pen)	$549 (5 mg dose pen)		21
	Prescription Discount	Varies by pharmacy (e.g., GoodRx price ~$1,035)	Not insurance. Cannot be combined with Savings Card.	21
	Card (e.g., GoodRx)
Government-Funded Plan	Standard Copay / Cost	Varies by plan	Ineligible for Zepbound Savings Card.	21
(Medicare, Medicaid, TRICARE)
Low-Income, Uninsured	Lilly Cares Foundation	Potentially $0 for up to 12 months	Must meet strict income criteria. Zepbound not explicitly listed as available.	9
(U.S. Residents)	Patient Assistance Program

2.2. The Zepbound Savings Card: A Detailed Analysis

The Zepbound Savings Card is the primary affordability tool offered by Eli Lilly for patients with commercial insurance.

It is crucial to understand that the card functions in two distinct ways, depending on whether the patient’s insurance plan actually covers the medication.²⁴

2.2.1. Eligibility for Commercially Insured Patients with Coverage

For patients fortunate enough to have a commercial insurance plan that includes Zepbound on its formulary, the Savings Card can dramatically reduce their out-of-pocket costs.

By applying the card at the pharmacy, eligible patients can pay as little as $25 for a one-month or even a three-month prescription.²⁷

This offer is subject to limitations, including a maximum monthly savings of up to $150 and a separate maximum annual savings of around $1,800 to $1,950.²⁴

This program is designed to overcome copay barriers and encourage adherence for patients who have already cleared the primary hurdle of formulary coverage.

2.2.2. Eligibility for Commercially Insured Patients Without Coverage

For the large number of patients whose commercial insurance plan does not cover Zepbound (due to a formulary exclusion or an unmet prior authorization), the Savings Card serves a different purpose.

In this scenario, the card acts as a direct manufacturer discount, reducing the high retail price to a more manageable, though still substantial, amount.

Sources indicate this price is typically around $550 or $650 for a one-month supply of pens.²¹

This is achieved by applying a significant discount (up to $563) off the list price at the point of sale.²⁶

This strategy prevents patients who are denied coverage from abandoning the therapy altogether, keeping them within the Lilly ecosystem.

2.2.3. Ineligibility for Government Beneficiaries

A critical and unyielding restriction of the Zepbound Savings Card program is the exclusion of all patients enrolled in government-funded healthcare programs.²⁶

This includes individuals with Medicare (including Part D and Advantage plans), Medicaid, TRICARE, the Department of Veterans Affairs (VA), or any other state prescription drug assistance program.²¹

This exclusion is due to federal anti-kickback statutes and leaves a large population of patients without access to this primary savings mechanism.

2.3. Self-Pay and Direct-to-Consumer Pathways

Recognizing the significant portion of the market left uncovered by insurance, Eli Lilly has developed direct-to-consumer pathways that function outside the traditional insurance framework.

2.3.1. LillyDirect Pharmacy Solutions: A PBM Workaround

LillyDirect is the manufacturer’s own digital pharmacy platform, which allows patients with a valid prescription to purchase Zepbound directly.³

This is a strategic move to offer a cash-pay option that is more affordable than the retail list price, directly competing with the unregulated compounding market and capturing revenue from uninsured patients or those on high-deductible plans.

The most notable offering through LillyDirect is the availability of single-dose vials, which are priced significantly lower than the pre-filled pens.

Pricing is tiered by dose, with the 2.5 mg starting dose vial available for $349 and the maintenance doses (5 mg through 15 mg) priced at $499 per month.¹⁸

More recent information also indicates new, lower direct-to-consumer pricing for the single-use pens at $399 for the 2.5 mg dose and $549 for the 5 mg dose.²¹

This creates a complex but important trade-off for the self-pay patient: the vials are cheaper but require the patient to draw the medication into a syringe, a step that may be a barrier for some, while the pens offer convenience at a higher price point.

2.3.2. The Role of Prescription Discount Cards (GoodRx, SingleCare)

For patients paying cash, third-party prescription discount services like GoodRx, SingleCare, and Optum Perks can provide coupons that reduce the retail price at various pharmacies.²²

While these cards can offer savings, the final price may not be as low as the manufacturer’s direct programs like LillyDirect.²¹

These discount cards are a form of cash payment and cannot be combined with insurance or the Zepbound Savings Card.

2.4. Patient Assistance Programs (PAPs): The Last Resort

For patients with the greatest financial need, Patient Assistance Programs (PAPs) may offer a path to obtaining medication at little to no cost.

2.4.1. The Lilly Cares Foundation

The Lilly Cares Foundation is a nonprofit organization established by Eli Lilly to provide its prescribed medications for free to qualifying U.S. patients.⁹

Eligibility is typically restricted to uninsured or underinsured individuals who meet strict household income guidelines, often a multiple of the Federal Poverty Level (FPL).⁹

If approved, a patient can receive their medication free for up to 12 months before needing to reapply.¹⁰

However, a review of the available medication lists within the research material does not explicitly include Zepbound, making its availability through this program uncertain.¹⁰

Patients who believe they may qualify should contact Lilly Cares directly to inquire about Zepbound’s status.

2.4.2. Third-Party Foundations

Independent charitable foundations such as the Patient Access Network (PAN) Foundation and the HealthWell Foundation sometimes offer copay assistance for expensive medications.¹⁴

However, their assistance is typically contingent on the patient having an insurance plan that already covers the medication and the drug being on the foundation’s list of supported diseases.

These programs are designed to help with high copays, not to cover the full cost of an un-covered drug.¹⁴

Section 3: The Insurance Gauntlet: Navigating Payer Requirements

Insurance companies and the Pharmacy Benefit Managers (PBMs) that administer their drug plans employ a sophisticated set of utilization management tools to control costs and restrict access to high-priced specialty drugs like Zepbound.

These tools are not independent hurdles but an interconnected system of deterrence designed to ration care.

Understanding these mechanisms is the first step in building a strategy to overcome them.

The rise of these management tools for GLP-1 agonists reflects a fundamental tension in the U.S. healthcare system: the clash between evidence-based medicine, which increasingly recognizes obesity as a chronic disease requiring medical treatment, and a payer model that often seeks to contain costs by classifying weight management as a “lifestyle” or “cosmetic” issue.³⁴

3.1. Prior Authorization (PA): Proving Medical Necessity

A Prior Authorization (PA) is a process in which a healthcare provider must obtain pre-approval from a patient’s insurance company before a specific medication will be covered.³⁵

The stated purpose is to ensure the drug is being prescribed appropriately and is medically necessary for the patient’s condition.³⁷

For expensive drugs like Zepbound, PAs are nearly universal.³²

The process itself is a significant administrative burden, with medical practices dedicating substantial staff hours each week to completing PA paperwork.³⁸

Common criteria that must be met and documented in a PA submission for Zepbound include:

• BMI Thresholds: The patient’s BMI must align with the FDA-approved indications, typically a BMI of 30 kg/m2 or greater, or a BMI of 27 kg/m2 or greater in the presence of at least one weight-related comorbidity.³²
• Documented Comorbidities: The provider must supply evidence of qualifying weight-related health issues, such as chart notes or lab results confirming hypertension, dyslipidemia, type 2 diabetes, or obstructive sleep apnea.¹⁹
• Proof of Lifestyle Modification: Many payers require documentation that the patient has actively participated in a comprehensive weight management program, including a reduced-calorie diet and increased physical activity, for a specified period (commonly three to six months) before the medication request is submitted.³²

3.2. Step Therapy: The “Fail-First” Mandate

Step therapy is an insurance requirement that forces a patient to try and fail one or more lower-cost “preferred” medications before the insurer will agree to cover a more expensive, “non-preferred” drug like Zepbound.¹⁶

This “fail-first” approach is a blunt cost-containment strategy.⁴³

For obesity management, insurers may mandate trials of older and less effective medications, such as:

• Phentermine (Adipex-P)
• Phentermine/topiramate (Qsymia)
• Naltrexone/bupropion (Contrave)
• Orlistat (Xenical) ¹⁶

In a more challenging scenario, some plans may require a patient to try a competing GLP-1 agonist first, such as Wegovy or Saxenda.¹⁶

This makes clinical data from head-to-head trials, like the SURMOUNT-5 study showing Zepbound’s superiority over Wegovy, a vital piece of evidence for an appeal.⁶

The recent formulary changes by major PBMs like CVS Caremark, which explicitly require a switch from Zepbound to Wegovy, are a clear and aggressive implementation of this strategy.⁴⁵

3.3. Formulary Tiers and Exclusions: The PBM’s Influence

The formulary is the list of prescription drugs that an insurance plan agrees to cover.³⁵

Zepbound’s position on—or absence from—this list is the most fundamental determinant of access.

These formulary decisions are often driven by the financial negotiations and rebate agreements between PBMs and pharmaceutical manufacturers, rather than purely by clinical evidence.¹⁵

• Formulary Exclusion: This is the most formidable barrier. A formulary exclusion means the plan has made a business decision not to cover the drug under most circumstances.⁴⁶ The announced 2025 changes by Aetna and CVS Caremark to remove Zepbound are examples of formulary exclusions.⁴⁸ Overcoming an exclusion requires a formal appeal for a “formulary exception,” which is a difficult but not impossible process.
• Tiering: Even when a drug is on the formulary, its placement within a tiered system dictates the patient’s out-of-pocket cost. Formularies are typically divided into tiers, with lower tiers (Tier 1, Tier 2) reserved for generic and preferred brand drugs with low copays. Expensive, non-preferred brand-name drugs like Zepbound are usually placed in higher tiers (Tier 3, Tier 4, or a Specialty Tier), which require the patient to pay a much higher copay or a percentage of the drug’s cost (coinsurance).¹³
• Plan Exclusions: Beyond individual drug exclusions, some employer-sponsored health plans have a blanket policy that excludes coverage for all medications prescribed for the treatment of obesity or weight loss.¹⁵ Identifying such a plan-level exclusion is the first step, as it represents a fundamental policy barrier that must be addressed, sometimes by advocating with the employer’s HR department to change the benefits package for the following year.³⁴

A denial can result from any one of these tools or a combination of them.

A plan may have Zepbound on its formulary (no exclusion) but still require a patient to satisfy both a prior authorization and a step therapy protocol.

The provider might submit a PA with all the required clinical documentation, only to have it denied because the patient has not yet tried and failed the mandated step therapy drug.

This illustrates how the layers interact to create a formidable and often frustrating barrier to accessing care.

Pinpointing which specific barrier caused the denial is the essential first step in crafting a successful appeal.

Section 4: Payer-Specific Coverage Analysis: A Deep Dive

The insurance landscape for Zepbound is not monolithic; it is a complex and dynamic patchwork of policies that vary significantly by payer, plan type, and even geographic location.

Coverage decisions are in constant flux, driven by fierce competition between drug manufacturers and the powerful PBMs that control market access.

This section provides specific intelligence on the coverage policies of major U.S. payers, with a particular focus on critical, time-sensitive formulary changes that will impact patient access in the near future.

The following table offers a high-level summary of the Zepbound coverage landscape, allowing for a quick orientation before delving into the specifics of each payer.

Table 4.1: Major Payer Zepbound Coverage at a Glance

Payer / PBM	General Coverage Status	Known Step Therapy Requirements	CRITICAL Formulary Updates (as of July 2025)
Cigna / Express Scripts	Varies by plan; often requires PA. Added to preferred formulary in late 2023.	May be required depending on plan.	No major exclusion announced.
UnitedHealthcare / Optum Rx	Varies by plan; requires PA.	Yes, some plans require trial of phentermine first.	No major exclusion announced; became a preferred GLP-1 over Wegovy/Saxenda on some plans.
Aetna	Varies by plan; requires PA.	Yes, may require trial of metformin, phentermine, etc.	REMOVED from formulary for weight management on many plans. Wegovy/Saxenda are preferred.
CVS Caremark	Varies by plan; requires PA.	Yes, forced switch to Wegovy.	REMOVED from preferred formulary. Requires appeal for formulary exception to continue Zepbound.
BCBS Federation	Highly fragmented; varies by state/plan.	Varies by plan.	Some affiliates (e.g., BCBS of Michigan) are REMOVING all GLP-1s for weight loss.
Humana	Varies by plan; PA typically required.	Varies by plan.	No major exclusion announced.
Medicare	NOT COVERED for weight loss by law.	N/A	Coverage may be possible for other approved indications (e.g., OSA), but this is not guaranteed.
Medicaid	Varies by state; often not covered.	Varies by state.	Covered without PA in California (Medi-Cal); coverage expanding in some other states.
TRICARE	Covered for Prime/Select with PA.	Varies.	Not covered for TRICARE for Life.

4.1. Cigna and Express Scripts

Initially, Cigna and its PBM, Express Scripts, showed favorable positioning for Zepbound.

Effective December 1, 2023, Zepbound was added to the Express Scripts National Preferred Formulary, signaling a willingness to cover the medication for its commercial plan members.¹

However, coverage remains highly dependent on the specific employer-sponsored plan.

When covered, Zepbound is often classified as a non-preferred brand-name drug, which necessitates a prior authorization to establish medical necessity.⁵⁰

The typical PA criteria for Cigna plans require that a patient be at least 18 years old, have engaged in lifestyle modifications (diet and exercise) for at least three months, and meet the BMI thresholds (≥30, or ≥27 with a comorbidity like hypertension, high cholesterol, or type 2 diabetes).⁵⁰

Cigna’s policy also explicitly denies coverage if a patient is concurrently taking another GLP-1 medication or any other prescription weight loss drug.⁵²

To determine their specific coverage, Cigna members should log into the Express Scripts or Cigna member portal or call the customer service number on their insurance ID Card.²⁴

4.2. UnitedHealthcare (UHC) and Optum Rx

Coverage for Zepbound under UnitedHealthcare plans, managed by the PBM Optum Rx, is also highly variable and contingent on the patient’s specific plan benefits.⁵⁴

In a significant policy move, Optum Rx added Zepbound to its prior authorization formulary in July 2024, making coverage possible, though not automatic.²⁴

For some plans, such as the UnitedHealthcare Community Plan of Massachusetts, UHC has established Zepbound as a preferred GLP-1 agonist for weight loss over its competitors, Wegovy and Saxenda.⁴⁰

This is a notable development, as it removes the need to fail on those alternatives first.

However, these plans have instituted a different step therapy requirement: new users must first trial the less expensive oral medication phentermine (with or without topiramate) before a PA for Zepbound will be considered.⁴⁰

Standard PA criteria for UHC plans typically include a diagnosis of an overweight or obese condition, being 18 years or older, meeting the baseline BMI requirements, and confirmation that the member has been counseled to continue a reduced-calorie diet and increased physical activity.⁴⁰

The FDA-approved indication for obstructive sleep apnea also serves as a viable pathway for coverage under UHC.⁴⁰

UHC members must check their plan-specific Prescription Drug List (PDL) by signing into their online account to verify their benefits.⁵⁵

4.3. Aetna

Aetna’s coverage policy for Zepbound represents a critical and adverse shift for patients.

While some Aetna plans have historically covered Zepbound as a preferred drug (contingent on a PA demonstrating BMI requirements and a six-month trial of a formal weight management program), this is changing dramatically.³²

CRITICAL UPDATE: Effective July 1, 2025, Aetna is removing Zepbound from its formulary for the indication of weight management on many of its commercial plans, including the widely used Advanced Control Plan.⁴⁸

This is a financially motivated decision designed to generate significant cost savings for Aetna and its clients.⁴⁸

Under this new policy, the preferred and covered GLP-1 medications for weight management will be Wegovy and Saxenda.⁴⁸

Patients currently taking Zepbound will find their prescriptions are no longer covered.

To continue therapy, their provider must submit a request for a medical exception, arguing why the covered alternatives are not appropriate for that specific patient.

If the exception is denied, the patient will be forced to either switch to Wegovy or Saxenda or pay the full out-of-pocket cost for Zepbound.⁵⁶

Patients can check their specific formulary status using Aetna’s online medication search tool.³²

4.4. CVS Caremark

In a similar and even more disruptive move, CVS Caremark, one of the largest PBMs in the country, is also overhauling its Zepbound coverage.

CRITICAL UPDATE: Effective July 1, 2025, CVS Caremark is removing Zepbound from its standard preferred formulary.⁴⁵

This change is not based on clinical effectiveness but is the result of formulary contracts and rebate negotiations between the PBM and the drug manufacturers.⁴⁵

This policy mandates a “forced switch”: patients currently stable on Zepbound will be required to change to Wegovy to maintain coverage.⁴⁵

Existing prior authorizations for Zepbound will be cancelled as of June 30, 2025.²⁰

This type of non-medical switching is medically risky, as it can lead to weight regain, the return of comorbidities, and new or intolerable side effects for the patient.⁴⁹

The pathway to remain on Zepbound under a CVS Caremark plan is to appeal the formulary exclusion.

This involves a multi-step process:

1. The provider must submit a new prior authorization for Zepbound, which will be denied. This denial is a necessary procedural step.⁴⁵
2. Upon denial, the provider and patient can initiate a formal appeal for a formulary exception. This appeal must be supported by a strong Letter of Medical Necessity.⁴⁵
3. The strongest arguments for the appeal include: documented failure, intolerance, or contraindication to Wegovy; a diagnosis of moderate-to-severe OSA (an indication for which Zepbound is approved and Wegovy is not); or documented clinical success on Zepbound (e.g., achieving and maintaining at least 5% weight loss).⁴⁵

In a peculiar twist driven by formulary contracts, some reports indicate that if a Zepbound appeal is successful, CVS Caremark may cover Mounjaro (the same drug) in its place, even for patients without a diabetes diagnosis.⁴⁵

4.5. The Blue Cross Blue Shield (BCBS) Federation: A Patchwork of Policies

There is no single, national coverage policy for Zepbound under Blue Cross Blue Shield.

The BCBS Association is a federation of 34 independent, locally operated companies, and coverage for weight loss medications is extremely fragmented, varying widely by state and by individual plan.¹³

When a BCBS plan does cover Zepbound, a prior authorization is almost always required, with criteria that typically include meeting BMI thresholds, having a qualifying comorbidity, and documenting previous, unsuccessful weight loss attempts through lifestyle modification.¹³

The variability is best illustrated by state-specific examples:

• Blue Cross Blue Shield of Michigan (BCBSM): For its fully insured large group commercial members, BCBSM implemented stricter PA criteria in August 2024, including a higher BMI threshold of 35 or greater and requiring formal documentation (not just physician attestation) of a six-month lifestyle program. More drastically, the insurer announced it will cease covering all GLP-1 drugs for weight loss for these members starting January 1, 2025.⁵⁷
• Blue Cross Blue Shield of Massachusetts: In contrast, BCBS of Massachusetts is not implementing a full exclusion. Instead, effective July 1, 2025, it will impose a quantity limit, restricting fills of Zepbound, Wegovy, and Saxenda to a 30-day supply at a time. This is a utilization management strategy intended to reduce medication waste, not eliminate access.⁵⁸
• Blue Cross Blue Shield of Illinois: This affiliate requires members to check their specific plan’s drug list (e.g., 4-tier or 6-tier formulary) to determine if Zepbound is covered and what special requirements, such as PA or step therapy, apply.⁶⁰

Given this extreme fragmentation, it is essential for BCBS members to obtain their specific plan’s formulary documents and contact their local BCBS company directly to understand their benefits.¹³

4.6. Humana

The available information on Humana’s Zepbound coverage is less definitive than for other major payers.

Some plan formularies for Humana’s Medicare and Managed Medicaid products list Zepbound as covered, sometimes without explicit PA or step therapy requirements noted.⁶¹

However, this information may not be representative of their commercial employer-sponsored plans.

Other sources suggest that for commercial plans, coverage is possible but will almost certainly require a prior authorization to demonstrate medical necessity, often tied to a specific diagnosis like type 2 diabetes or another metabolic condition.⁶²

Patients with Humana insurance must verify coverage directly with their plan.

4.7. Government-Sponsored Plans

Patients with government-sponsored insurance face a distinct set of challenges, most notably their ineligibility for the manufacturer’s Zepbound Savings Card.²¹

4.7.1. Medicare

Federal law currently prohibits Medicare Part D from covering prescription drugs when they are prescribed solely for anorexia, weight loss, or weight gain.²⁵

This statutory exclusion is a major barrier for Medicare beneficiaries seeking Zepbound for chronic weight management.

A 2026 proposal to allow coverage was reversed, keeping the ban in place.⁶⁵

However, a critical loophole exists: Medicare Part D plans can cover these medications if they are prescribed for another medically accepted indication.

For example, after Wegovy received an FDA indication for reducing the risk of major adverse cardiovascular events, CMS issued guidance allowing Part D plans to cover it for that specific use.⁶⁵

It is plausible that Zepbound’s FDA approval for moderate-to-severe obstructive sleep apnea could create a similar pathway for coverage under some Medicare plans, though this is not yet clearly established or guaranteed.¹³

4.7.2. Medicaid

Medicaid coverage for anti-obesity medications is determined on a state-by-state basis, leading to dramatic geographic disparities in access.²⁴

Many state Medicaid programs do not cover these drugs, while others that do often impose strict prior authorization criteria and quantity limits.⁶⁴

A significant positive outlier is California’s Medicaid program (Medi-Cal), which covers Zepbound without requiring a prior authorization, providing some of the most liberal access in the country.¹³

A number of other states, including Delaware, Michigan, Minnesota, Pennsylvania, and Virginia, are known to cover Wegovy and may therefore be more likely to cover Zepbound as well.²⁴

Patients must consult their specific state’s Medicaid Preferred Drug List (PDL) to determine coverage.³⁰

4.7.3. TRICARE

TRICARE, the healthcare program for uniformed service members, retirees, and their families, covers Zepbound for beneficiaries enrolled in TRICARE Prime or TRICARE Select plans, provided they meet the clinical criteria and a prior authorization is approved by their provider.⁶⁷

However, Zepbound is not covered for individuals with TRICARE for Life coverage.⁶⁷

Section 5: When Coverage is Denied: A Strategic Guide to Appeals

An insurance denial for Zepbound is not the end of the road; it is the beginning of a procedural and legal process.

An appeal is a patient’s right under the Affordable Care Act, and data shows that a significant percentage of internal appeals are successful, with success rates ranging from 39% to 59%.¹⁶

The key to a successful appeal is to transform it from a simple request into a robust, evidence-based argument that systematically dismantles the insurer’s reason for denial.

This requires a strategic, organized approach from both the patient and their healthcare provider.

5.1. Understanding the Denial: Decoding the Explanation of Benefits

The first and most critical step is to obtain the official denial letter, often called an Explanation of Benefits (EOB), from the insurance company.¹⁵

This document is legally required to state the specific reason for the denial.

Initial denials are frequently generated by automated computer systems that may not have considered the patient’s full clinical picture, which is why an appeal that is reviewed by a human clinician can be successful.¹⁶

Common reasons for denial and the corresponding appeal strategy include:

• “Not Medically Necessary”: The insurer claims the patient does not meet the clinical criteria. The appeal must counter this by providing comprehensive medical documentation proving that the criteria (BMI, comorbidities, etc.) are indeed met.¹⁵
• “Formulary Exclusion”: The drug is not on the plan’s list of covered medications. The appeal must be framed as a “Formulary Exception Request.” The argument must focus on why the plan’s preferred alternatives are medically inappropriate for the patient (e.g., due to contraindications, past failures, or inferior efficacy).¹⁶
• “Failure to Try Step Therapy”: The insurer requires a trial of a different drug first. The appeal must provide evidence that the patient has either (a) already tried and failed the required step drug(s), or (b) has a documented medical reason (a contraindication or history of adverse reaction) that makes the step drug unsafe, or (c) cite clinical evidence that Zepbound is significantly more effective for the patient’s condition than the required step drug.¹⁶
• “Weight Loss Plan Exclusion”: The entire category of weight loss drugs is excluded by the plan. This is the most difficult denial to overturn. The appeal must shift the narrative away from “weight loss” and toward “disease management.” The argument should be that covering Zepbound is a cost-effective measure to treat or prevent the progression of expensive comorbidities like type 2 diabetes, heart disease, and sleep apnea.¹⁶

5.2. Building Your Case: Essential Documentation and Evidence

A successful appeal is built on a foundation of solid evidence.

The patient and provider must work together to compile a comprehensive package of supporting documentation.¹⁵

Key documents include:

• A Detailed Letter of Medical Necessity (LMN): This is the cornerstone of the appeal. Written by the prescribing physician, this letter should tell the patient’s clinical story, explaining precisely why Zepbound is the most appropriate and necessary treatment. It should integrate all the evidence below into a compelling narrative.³
• Complete Medical Records: This includes all relevant chart notes that document the patient’s diagnosis of obesity, their current and historical BMI, and the presence of all weight-related comorbidities.¹⁶
• Diagnostic and Laboratory Results: Objective data is crucial. This includes recent lab work (e.g., HbA1c levels for prediabetes, lipid panels for dyslipidemia) and, if applicable, the full report from a polysomnogram (sleep study) confirming a diagnosis of moderate-to-severe OSA.¹⁶
• A Thorough History of Failed Treatments: This documentation directly counters step therapy denials. It should be a detailed list of all past weight loss attempts, including:

• Trials of other medications (names, dosages, duration of use, and reason for discontinuation, such as lack of efficacy or intolerable side effects).¹⁶
• Participation in formal, supervised weight loss programs (e.g., Weight Watchers, Noom, or a hospital-based program), including dates and outcomes.¹⁶
• Records of gym memberships, personal training sessions, or consultations with dietitians.¹⁶
• Evidence of Continuity of Care: If the denial is for a patient who was already taking Zepbound (perhaps through free samples, a clinical trial, or self-pay) and achieving positive results, this is a powerful argument. The appeal should include documentation of the weight loss achieved, improvements in metabolic markers, and any reduction in comorbidity symptoms. This frames the denial as a disruption of effective, ongoing care.⁴⁶

5.3. Crafting the Appeal: A Step-by-Step Guide

The appeal itself should be a formal, well-structured letter that systematically addresses the insurer’s denial.¹⁶

1. Address and Identify: Clearly address the letter to the correct appeals department (found on the denial notice) and include all relevant identifiers: the patient’s name, policy number, and the case or appeal number from the denial letter.
2. State the Purpose: Begin by clearly stating that the letter is a formal appeal of the decision to deny coverage for Zepbound and request a formulary exception for medical necessity.
3. Summarize the Clinical Case: Provide a concise summary of the patient’s medical situation, including their BMI, all relevant comorbidities, and the specific reasons Zepbound was prescribed.
4. Rebut the Denial: Directly address the insurer’s stated reason for denial and present the specific evidence from your documentation package that refutes it.
5. Cite Clinical Evidence: Strengthen the case by citing peer-reviewed academic research that supports the use of Zepbound for the patient’s specific condition. For example, reference the SURMOUNT-5 trial if arguing against a Wegovy step therapy requirement, or studies on tirzepatide and OSA if that is the primary diagnosis.¹⁶
6. Submit the Appeal: Follow the insurer’s specified submission process, whether it is via an online portal, fax, or certified mail. Keep a copy of the entire submission and a record of the submission date.¹⁶ Insurers typically have 30-60 days to respond to an internal appeal.

5.4. Leveraging Continuity of Care and Non-Medical Switching Laws

For patients facing a forced switch due to formulary changes (like those imposed by Aetna and CVS Caremark), the appeal should invoke the principle of “continuity of care”.⁴⁹

The argument is that disrupting a therapy that is proven to be safe and effective for that individual, for purely financial (non-medical) reasons, poses an unnecessary clinical risk.

Some states have laws or regulations that offer patients protection against such non-medical switching, and these should be researched and cited in the appeal if applicable.⁴⁹

This legal and ethical argument can be particularly persuasive, as it shifts the focus to patient safety and the potential harm caused by the insurer’s policy.

Section 6: Strategic Alternatives and Comparative Analysis

When Zepbound coverage is denied and an appeal is unsuccessful, or if a plan has a hard exclusion, patients and providers must consider strategic alternatives.

The choice of an alternative medication is a complex decision that involves balancing clinical efficacy, side effect profiles, cost, and the likelihood of securing insurance coverage.

The following analysis and table compare Zepbound to its most common alternatives to facilitate this shared decision-making process.

Table 6.1: Comparative Analysis of Leading Anti-Obesity Medications

Feature	Zepbound (tirzepatide)	Wegovy (semaglutide)	Saxenda (liraglutide)	Qsymia (phentermine/topiramate)	Contrave (naltrexone/bupropion)
Manufacturer	Eli Lilly	Novo Nordisk	Novo Nordisk	Vivus	Currax
Mechanism	Dual GIP/GLP-1 Agonist	GLP-1 Agonist	GLP-1 Agonist	Sympathomimetic / Anti-epileptic	Opioid Antagonist / Antidepressant
Administration	Once-weekly injection	Once-weekly injection	Once-daily injection	Once-daily oral capsule	Twice-daily oral tablet
Avg. Efficacy	15% – 21% weight loss	~15% weight loss	~5% – 8% weight loss	~9% – 11% weight loss	~5% – 8% weight loss
List Price/Month	~$1,087	~$1,349	~$1,349	~$275	~$842
Common Hurdles	PA, Step Therapy, Recent Formulary Exclusions (Aetna, CVS)	PA, Step Therapy, Preferred on some Aetna/CVS plans	PA, Step Therapy, Often non-preferred	PA, Step Therapy	PA, Step Therapy
Source(s)	2	66	70	73	44

6.1. Head-to-Head: Zepbound (tirzepatide) vs. Wegovy (semaglutide)

Zepbound and Wegovy are the two most powerful and prominent medications in the new generation of anti-obesity treatments.

• Efficacy: The primary clinical advantage of Zepbound is its superior efficacy. The head-to-head SURMOUNT-5 trial demonstrated that tirzepatide leads to significantly greater weight loss than semaglutide.⁶ This makes Zepbound the preferred clinical choice for many providers and patients seeking maximum weight reduction.
• Cost: Zepbound’s list price of approximately $1,087 is about 20% lower than Wegovy’s list price of roughly $1,349.²¹ This cost advantage was initially a key part of Lilly’s strategy to gain favorable formulary placement.
• Coverage: The coverage landscape is now the most critical differentiator. While Wegovy has been on the market longer, the recent formulary changes by Aetna and CVS Caremark have made Wegovy the required and preferred GLP-1 on those massive plans.⁴⁸ This means that for millions of patients, Wegovy is now the more accessible option, despite its higher price and slightly lower efficacy.

6.2. Other GLP-1 Agonists: Saxenda (liraglutide)

Saxenda is an older GLP-1 receptor agonist that requires a once-daily injection, as opposed to the once-weekly schedule of Zepbound and Wegovy.⁷⁰

• Profile: Its efficacy is generally considered to be lower than the weekly injectables, with typical weight loss in the range of 5% to 8%.⁷¹ Its list price is high, comparable to Wegovy’s at around $1,349 per month.⁷¹
• Coverage: Saxenda is often a non-preferred alternative on many formularies and is subject to the same PA and step therapy requirements as other GLP-1s.⁶⁷ The manufacturer, Novo Nordisk, discontinued its primary savings card program for new enrollees in June 2023, potentially increasing out-of-pocket costs.⁷⁶ It remains a covered alternative on the new Aetna formulary.⁴⁸

6.3. Oral Anti-Obesity Medications (AOMs): Qsymia and Contrave

These oral medications are frequently positioned by insurers as the mandatory first step in a step-therapy protocol before a more expensive injectable will be considered.¹⁶

• Qsymia (phentermine/topiramate): This once-daily oral capsule combines two older medications. It is significantly less expensive than the GLP-1s, with a list price around $275 per month.⁷⁴ While it has better coverage rates in commercial plans than the injectables, a PA is still often required.⁷³ Manufacturer savings programs are available that can lower the cost for both insured and cash-paying patients.⁷⁷
• Contrave (naltrexone/bupropion): This twice-daily oral tablet is another common step-therapy drug. Its efficacy is modest (5-8% weight loss).⁴⁴ While its list price is high (around $842), the manufacturer offers aggressive savings programs that can bring the cash-pay price down to as low as $99 per month through specific partner pharmacies, making it an affordable option for many.⁷⁵

The existence of these less expensive, albeit less effective, alternatives gives payers a powerful tool to deflect patients away from high-cost GLP-1s.

For a patient mandated to follow step therapy, a trial of one of these oral agents is often an unavoidable prerequisite to obtaining coverage for Zepbound or Wegovy.

Section 7: Conclusion and Strategic Recommendations

Securing insurance coverage for Zepbound is not a simple matter of obtaining a prescription.

It is a complex, often adversarial process that requires a strategic, persistent, and highly informed approach.

The landscape is defined by a fundamental conflict between the growing medical consensus that obesity is a chronic disease requiring effective treatment and a payer system designed to aggressively control the high costs associated with a new class of revolutionary but expensive medications.

7.1. Key Findings Summary

The analysis reveals several critical dynamics.

First, access to Zepbound is dictated less by clinical need and more by the financial arrangements between pharmaceutical manufacturers and pharmacy benefit managers.

The recent formulary removals of Zepbound by Aetna and CVS Caremark in favor of Wegovy are stark evidence of this “formulary war,” where non-medical switching is imposed on patients for purely economic reasons.

Second, a patient’s specific diagnosis is a strategic asset.

The existence of three distinct FDA-approved indications for the same molecule (tirzepatide)—type 2 diabetes (Mounjaro), chronic weight management (Zepbound), and obstructive sleep apnea (Zepbound)—creates a hierarchy of coverage probability.

A prescription for OSA or diabetes is far more likely to be approved than one for obesity alone, as it can bypass common weight-loss plan exclusions.

Third, Eli Lilly has implemented a sophisticated, multi-tiered affordability structure (Savings Cards, LillyDirect self-pay options, and a Patient Assistance Program) that functions as a parallel system to traditional insurance.

This strategy allows the company to capture revenue from various patient segments while providing pathways to access for those shut out by the insurance system.

Finally, the insurance denial and appeals process is a central feature of the access journey.

An initial denial is a common and expected outcome, and success often hinges on the ability of the patient and provider to build a robust, evidence-based case that systematically refutes the insurer’s stated reasons for rejection.

7.2. Actionable Recommendations for Patients and Providers

Navigating this environment requires proactive and diligent effort.

The following checklists provide a summary of strategic actions for patients and best practices for providers.

Patient Action Checklist:

1. Conduct Immediate Reconnaissance: As soon as Zepbound is considered, contact your insurance provider. Use the phone number on your ID card to ask a representative directly about your specific plan. Ask: “Is Zepbound on my plan’s formulary? Does it require a prior authorization? Does it have a step therapy requirement?”.²⁹
2. Collaborate on Diagnosis: Discuss your full medical history with your provider. If you have a diagnosis of moderate-to-severe obstructive sleep apnea or type 2 diabetes in addition to obesity, ensure this is accurately documented and considered as the primary diagnosis for the prescription, as it may open a more favorable coverage pathway.¹³
3. Prepare for a Denial: Assume an initial denial is possible, if not likely. When you receive the denial letter (Explanation of Benefits), do not be discouraged. Read it carefully to understand the exact reason for the denial, as this will be the foundation of your appeal.¹⁵
4. Systematically Pursue the Appeal: Work closely with your provider’s office to gather all necessary documentation—medical records, lab results, a history of past weight loss attempts, and a strong Letter of Medical Necessity. Submit a formal appeal and be persistent.¹⁶
5. Investigate All Financial Options: Simultaneously, explore every cost-saving pathway that applies to your situation. If you have commercial insurance, enroll in the Zepbound Savings Card online. If you are uninsured or facing a high deductible, research the cash-pay prices for vials and pens through LillyDirect. If you are low-income and uninsured, inquire about your eligibility for the Lilly Cares Foundation Patient Assistance Program.¹⁰
6. Address Formulary Changes Proactively: If your insurance is managed by Aetna or CVS Caremark, you must act immediately. Contact your provider to discuss the impending July 2025 formulary removal. Plan your appeal strategy now to request a formulary exception for continuity of care.⁴⁸

Provider Best Practices Checklist:

1. Meticulous Prior Authorization Submissions: Be exhaustive in PA submissions. Include specific ICD-10-CM diagnosis codes for obesity and all relevant comorbidities (e.g., hypertension, dyslipidemia, OSA), recent and relevant lab values (e.g., A1c, lipid panel), and polysomnogram results if applicable.¹⁹
2. Proactive Documentation: From the first patient visit, begin documenting all lifestyle modification efforts, including counseling on diet and exercise. Maintain a detailed medication history, noting any past trials of other anti-obesity medications, the duration of use, and the clinical reason for discontinuation.⁴⁶
3. Master the Letter of Medical Necessity (LMN): Prepare to write compelling LMNs, especially for formulary exception and step therapy appeals. The letter should tell a clear clinical story, referencing the patient’s unique history, the failure or contraindication of preferred alternatives, and citing peer-reviewed literature (e.g., head-to-head trial data) to support the choice of Zepbound.⁴⁵
4. Set Realistic Patient Expectations: Educate patients from the outset about the realities of the insurance access process. Inform them about potential costs, the high likelihood of an initial denial, the necessity of an appeal, and the time it may take to secure coverage. This manages expectations and helps build a collaborative patient-provider relationship to tackle the administrative hurdles together.³⁸
5. Stay Informed on Payer Policies: The coverage landscape is fluid. Designate a staff member or utilize resources to stay current on the formulary changes and PA criteria of the major payers in your region, particularly the critical updates from Aetna, CVS Caremark, and local BCBS affiliates.

Works cited

1. Zepbound™ (tirzepatide) is Now Available in U.S. Pharmacies for Adults Living with Obesity, accessed August 13, 2025, https://investor.lilly.com/news-releases/news-release-details/zepboundtm-tirzepatide-now-available-us-pharmacies-adults-living
2. Zepbound (tirzepatide) FDA Approval History – Drugs.com, accessed August 13, 2025, https://www.drugs.com/history/zepbound.html
3. Lilly to offer all approved doses of Zepbound (tirzepatide) single-dose vials through LillyDirect Self Pay Pharmacy Solutions | Eli Lilly and Company, accessed August 13, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-offer-all-approved-doses-zepbound-tirzepatide-single-dose
4. Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients, accessed August 13, 2025, https://investor.lilly.com/news-releases/news-release-details/lilly-launches-additional-zepbound-vial-doses-and-offers-new
5. FDA Approves New Medication for Chronic Weight Management, accessed August 13, 2025, https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
6. Zepbound for Weight Loss: Uses, Dosage, Side Effects – Drugs.com, accessed August 13, 2025, https://www.drugs.com/zepbound.html
7. Who Makes Zepbound (tirzepatide)? – Form Health, accessed August 13, 2025, https://www.formhealth.co/faqs/who-makes-zepbound
8. A Medicine Company | Eli Lilly and Company, accessed August 13, 2025, https://www.lilly.com/
9. Contact Us | Eli Lilly and Company, accessed August 13, 2025, https://www.lilly.com/about/contact
10. What is Lilly Cares | Lilly Cares, accessed August 13, 2025, https://www.lillycares.com/
11. Zepbound 2025 Prices, Coupons & Savings Tips – GoodRx, accessed August 13, 2025, https://www.goodrx.com/zepbound
12. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, accessed August 13, 2025, https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
13. Does Blue Cross Blue Shield cover Zepbound? – SingleCare, accessed August 13, 2025, https://www.singlecare.com/blog/does-blue-cross-blue-shield-cover-zepbound/
14. ZEPBOUND Coupon, Savings Card and Patient Assistance – NowPatient, accessed August 13, 2025, https://nowpatient.com/medications/zepbound
15. What to Do When Your Insurance Denies Zepbound or Wegovy – A Pound of Cure | A Bariatric Surgery and Non-Surgical Weight Loss practice in Tucson, AZ, accessed August 13, 2025, https://poundofcureweightloss.com/insurance-denies-zepbound-or-wegovy/
16. 5 Steps to Appeal a Zepbound Denial — Honest Care, 2025, accessed August 13, 2025, https://www.findhonestcare.com/blog-posts/steps-to-appeal-your-zepbound-claim-denial
17. FDA approves Zepbound for obstructive sleep apnea, accessed August 13, 2025, https://www.pharmacist.com/Blogs/CEO-Blog/fda-approves-zepbound-for-obstructive-sleep-apnea
18. How Much Does Zepbound Cost Without Insurance? – Sesame, accessed August 13, 2025, https://sesamecare.com/blog/zepbound-cost-without-insurance
19. ZEPBOUND® (tirzepatide), accessed August 13, 2025, https://fm.formularynavigator.com/FormularyNavigator/DocumentManager/Download?clientDocumentId=Eq4Q_0lIkk-OUmXhIYYr5w
20. Zepbound Access – Eli Lilly, accessed August 13, 2025, https://zepbound.lilly.com/access
21. How Much Does Zepbound (Tirzepatide) Cost Without Insurance? – GoodRx, accessed August 13, 2025, https://www.goodrx.com/zepbound/weight-loss-tirzepatide-cost
22. How Much Does Zepbound Cost With and Without Insurance? | Ro, accessed August 13, 2025, https://ro.co/weight-loss/zepbound-cost-with-and-without-insurance/
23. With or Without Insurance | Zepbound® (tirzepatide) injection – Lilly Pricing Info, accessed August 13, 2025, https://pricinginfo.lilly.com/zepbound
24. Zepbound: Savings, Discounts, Coupons & More — 2025 Guide – Honest Care, accessed August 13, 2025, https://www.findhonestcare.com/blog-posts/how-to-save-on-zepbound
25. Zepbound® Costs 2025: With and Without Insurance Coverage – Noom, accessed August 13, 2025, https://www.noom.com/blog/weight-management/zepbound-cost-with-and-without-insurance/
26. FOR ZEPBOUND SAVINGS INFORMATION, accessed August 13, 2025, https://zepbound.lilly.com/assets/pdf/Zepbound%20Downloadable%20Savings%20Information%20111623.pdf
27. How much is Zepbound with or without insurance? – Drugs.com, accessed August 13, 2025, https://www.drugs.com/medical-answers/zepbound-cost-without-insurance-insurance-3578715/
28. What is the Zepbound Coupon or Savings Card? – Drugs.com, accessed August 13, 2025, https://www.drugs.com/medical-answers/what-zepbound-coupon-savings-card-3578017/
29. Is Zepbound covered by insurance? – Drugs.com, accessed August 13, 2025, https://www.drugs.com/medical-answers/zepbound-covered-insurance-3577162/
30. Savings Card, Cost & Coverage Support | Zepbound® (tirzepatide) – Eli Lilly, accessed August 13, 2025, https://zepbound.lilly.com/coverage-savings
31. Authentic Zepbound® (tirzepatide) Shipped to You | Vial or Pen | LillyDirect®, accessed August 13, 2025, https://www.lilly.com/lillydirect/medicines/zepbound
32. Does Aetna cover Zepbound? – SingleCare, accessed August 13, 2025, https://www.singlecare.com/blog/does-aetna-cover-zepbound/
33. How to Apply – Lilly Cares, accessed August 13, 2025, https://www.lillycares.com/how-to-apply
34. Does Insurance Cover Weight Loss Medication? – Obesity Medicine Association, accessed August 13, 2025, https://obesitymedicine.org/blog/does-insurance-cover-weight-loss-medication/
35. What if You Get Denied a Prescription for Zepbound (tirzepatide)? – Form Health, accessed August 13, 2025, https://www.formhealth.co/faqs/what-if-denied-zepbound-prescription
36. Coverage Management Programs – Express Scripts, accessed August 13, 2025, https://www.express-scripts.com/art/open_enrollment/Coverage_Management_LMH.pdf
37. Frequently Asked Questions | Express Scripts by Evernorth, accessed August 13, 2025, https://www.express-scripts.com/frequently-asked-questions
38. Glucagon-Like Peptide-1 Receptor Agonists: A Pharmacy Perspective on Insurance Coverage and Medication Access, accessed August 13, 2025, https://info.primarycare.hms.harvard.edu/perspectives/articles/glp-1-pharmacy-perspective
39. Why Do Most Insurance Companies Deny Coverage for Zepbound & Wegovy, accessed August 13, 2025, https://puravidaflemingisland.com/blog/why-do-most-insurance-companies-deny-coverage-for-zepbound-wegovy
40. Zepbound and phentermine added to preferred drug list – UHCprovider.com, accessed August 13, 2025, https://www.uhcprovider.com/en/resource-library/news/2025/ma-medicaid-zepbound-phentermine.html
41. Does BCBS (Blue Cross Blue Shield) Cover Zepbound? – Honest Care, accessed August 13, 2025, https://www.findhonestcare.com/weight-loss/does-bcbs-cover-zepbound
42. PRIOR AUTHORIZATION CRITERIA, accessed August 13, 2025, https://www.shpnc.gov/documents/files/wegovy/open
43. What is Step Therapy? How to Get Insurance to Pay for Your “Non-Preferred” Drug – GoodRx, accessed August 13, 2025, https://www.goodrx.com/drugs/savings/what-is-step-therapy
44. A Guide to Obesity Step Therapy – Vida Health, accessed August 13, 2025, https://static.vida.com/wp-content/uploads/2023/12/11142128/CSS-1965_Guide-to-Obesity-Step-Therapy_SAMPLE.pdf
45. What You Need to Know: Navigating Zepbound Coverage Changes with CVS Caremark, accessed August 13, 2025, https://www.doctorlarocca.com/blog/Zepbound%20CVS%20Caremark%20update
46. Zepbound Formulary Denials Explained – Honest Care, accessed August 13, 2025, https://www.findhonestcare.com/denial-reasons/zepbound-formulary-denials-explained
47. CVS Caremark drops coverage of popular weight loss drug – Fox Business, accessed August 13, 2025, https://www.foxbusiness.com/lifestyle/cvs-caremark-drops-coverage-popular-weight-loss-drug
48. Aetna removes Zepbound from coverage for weight management – Bukaty Companies, accessed August 13, 2025, https://insights.bukaty.com/bulletins/aetna-removes-zepbound-from-coverage-for-weight-management
49. CVS Caremark denied Zepbound? Here’s what to do if you don’t want to switch to Wegovy., accessed August 13, 2025, https://www.getclaimable.com/post/cvs-caremark-denied-zepbound-here-s-what-to-do-if-you-don-t-want-to-switch-to-wegovy
50. Does Cigna cover Wegovy, Ozempic, Mounjaro & Zepbound? – SingleCare, accessed August 13, 2025, https://www.singlecare.com/blog/cigna-weight-loss-coverage/
51. Ready to talk to your insurance company about Wegovy®? – NovoCare, accessed August 13, 2025, https://www.novocare.com/content/dam/novonordisk/novocare/forms/Wegovy_Insurance_Coverage_Guide.pdf
52. Does Cigna cover Zepbound? – Ro, accessed August 13, 2025, https://ro.co/weight-loss/does-cigna-cover-zepbound/
53. Drug Coverage Guide – Express Scripts, accessed August 13, 2025, https://www.express-scripts.com/art/open_enrollment/MMONPF_DrugCoverageGuide.pdf
54. Does United Healthcare cover Zepbound? – SingleCare, accessed August 13, 2025, https://www.singlecare.com/blog/does-united-healthcare-cover-zepbound/
55. Pharmacy benefits | Member resources | UnitedHealthcare, accessed August 13, 2025, https://www.uhc.com/member-resources/pharmacy-benefits
56. There are upcoming changes to your plan’s drug coverage — and we want to be sure you’re ready – Aetna, accessed August 13, 2025, https://www.aetna.com/content/dam/aetna/pdfs/aetnacom/individuals-families-health-insurance/document-library/pharmacy/SOC-for-07.01.25-Advanced-Control-Aetna.pdf
57. Update: Changes coming for select weight loss drugs for some commercial members, accessed August 13, 2025, https://providerinfo.bcbsm.com/documents/alerts/2024/202406/alert-20240606-changes-weight-loss-drugs-commercial.pdf
58. Pharmacy Benefit Updates – Blue Cross Blue Shield of Massachusetts, accessed August 13, 2025, https://www.bluecrossma.org/disclaimer/plan-updates/pharmacy-benefit-updates
59. Plan Updates | Welcome to Blue Cross Blue Shield of Massachusetts – Employer Portal, accessed August 13, 2025, https://employer.bluecrossma.com/whats-new/plan-updates
60. 2025 Pharmacy Benefits | Blue Cross and Blue Shield of Illinois, accessed August 13, 2025, https://www.bcbsil.com/individual-family-health-insurance/learn-about-pharmacy-benefits
61. Humana Plans That Cover Zepbound – PrescriberPoint, accessed August 13, 2025, https://prescriberpoint.com/therapies/zepbound-487cd7e/coverage/humana
62. Does Humana Cover Zepbound? Costs & Rules – Meto, accessed August 13, 2025, https://meto.co/coverage/zepbound/humana
63. Humana Coverage for Metabolic & Longevity Care – Meto, accessed August 13, 2025, https://meto.co/coverage/humana
64. Obesity Care & Weight Loss: What’s Covered, and What’s Not? – GoodRx, accessed August 13, 2025, https://www.goodrx.com/conditions/weight-loss/weight-loss-treatments-insurance-coverage
65. Anti-Obesity Drugs Will Not be Covered by Medicare and Medicaid in 2026, accessed August 13, 2025, https://gi.org/2025/04/17/anti-obesity-drugs-will-not-be-covered-by-medicare-and-medicaid-in-2026/
66. How to get Wegovy covered by insurance – SingleCare, accessed August 13, 2025, https://www.singlecare.com/blog/how-to-get-wegovy-covered-by-insurance/
67. TRICARE Coverage of Weight Loss Medications: What To Know, accessed August 13, 2025, https://newsroom.tricare.mil/News/TRICARE-News/Article/4266447/tricare-coverage-of-weight-loss-medications-what-to-know
68. How do you get Wegovy covered by insurance? – Drugs.com, accessed August 13, 2025, https://www.drugs.com/medical-answers/you-wegovy-covered-insurance-3569905/
69. Wegovy® (semaglutide) injection 2.4 mg List Price & Insurance Coverage Explained, accessed August 13, 2025, https://www.novocare.com/obesity/products/wegovy/let-us-help/explaining-list-price.html
70. Weight-Loss Medicines | Cigna, accessed August 13, 2025, https://www.cigna.com/knowledge-center/hw/weight-loss-medicines-abq5186
71. Saxenda® Costs in 2025: Insurance vs. No Insurance – Noom, accessed August 13, 2025, https://www.noom.com/blog/weight-management/saxenda-cost-with-and-without-insurance/
72. Saxenda® (liraglutide) injection 3mg List Price & Insurance Coverage Explained | NovoCare®, accessed August 13, 2025, https://www.novocare.com/obesity/products/saxenda/explaining-list-price.html
73. Does Blue Cross Blue Shield Cover Phentermine/Topiramate ER (Qsymia) – Curex, accessed August 13, 2025, https://getcurex.com/drug-insurance/does-blue-cross-blue-shield-cover-phentermine-topiramate-er-qsymia
74. How much does Qsymia cost without insurance? – SingleCare, accessed August 13, 2025, https://www.singlecare.com/blog/qsymia-without-insurance/
75. How to save on Contrave – SingleCare, accessed August 13, 2025, https://www.singlecare.com/blog/contrave-savings/
76. Saxenda® (liraglutide) injection 3mg Cost, Coverage, & Savings Resources | NovoCare®, accessed August 13, 2025, https://www.novocare.com/obesity/products/saxenda.html
77. How Much Does Qsymia Cost With and Without Insurance? – GoodRx, accessed August 13, 2025, https://www.goodrx.com/qsymia/qsymia-cost
78. Prescription Weight Management — Qsymia® (Phentermine and Topiramate extended-release capsules) CIV, accessed August 13, 2025, https://qsymia.com/
79. Qsymia 2025 Prices, Coupons & Savings Tips – GoodRx, accessed August 13, 2025, https://www.goodrx.com/qsymia
80. Prescription weight-loss pills & medication | CONTRAVE® (naltrexone HCl/bupropion HCl), accessed August 13, 2025, https://contrave.com/
81. PA Submission Process Tips When Prescribing a GLP-1 RA for Type 2 Diabetes – novoMEDLINK, accessed August 13, 2025, https://www.novomedlink.com/content/dam/novonordisk/novomedlink/new/diabetes/patient/disease/library/documents/glp-1-prior-authorization-submission-process-brochure.pdf
82. GLP-1 medications and weight loss: Helping patients navigate beyond the trends, accessed August 13, 2025, https://www.wolterskluwer.com/en/expert-insights/glp-1-medications-and-weight-loss-help-patients-navigate-beyond-trends